Safety Lead-in Of The Mek Inhibitor Trametinib In Combination With Gsk2141795, An Akt Inhibitor, In Patients With Recurrent Endometrial Cancer: An NRG Oncology/gog Study
…The combination of trametinib and GSK2141795 had high levels of toxicity in endometrial cancer at the previously RP2D but was tolerable at a reduced dose. Due to insufficient preliminary efficacy at a tolerable dose, the Phase II study was not initiated….
read more